Supreme Court temporarily restores access to mifepristone
The Supreme Court temporarily restored telehealth and mail access to the abortion pill mifepristone on Monday, responding to an emergency appeal that warned of potential chaos for patients who had appointments to access the drug, reports BritPanorama.
The “administrative stay” is not a final decision but rather maintains the status quo for a few days while the court reviews emergency appeals filed Saturday by the drug’s manufacturer and the maker of a generic version. This order pauses a ruling from the conservative 5th US Circuit Court of Appeals that reinstated a nationwide requirement for in-person acquisition of the medication, which has become more widespread since the court overturned Roe v. Wade.
Justice Samuel Alito’s order staying the 5th Circuit ruling lasts through May 11, and Alito has requested a response in the cases by Thursday.
Danco Laboratories, the manufacturer of mifepristone, informed the Supreme Court in its appeal that the 5th Circuit order “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” GenBioPro, which produces a generic version of the drug, echoed these concerns, stating that the lower court’s decision posed a risk of “abruptly cutting off access for patients nationwide.”
This fast-track case brings the drug and the subject of abortion back to the forefront of the high court’s agenda less than two years after it upheld the drug’s availability. Alito is responsible for handling emergency appeals arising from the New Orleans-based 5th US Circuit Court.
Since the Covid-19 pandemic, patients have been able to obtain mifepristone through telehealth consultations. The Biden administration finalized regulations in 2023 eliminating the requirement for in-person visits, implemented one year following the Supreme Court’s decision to overturn Roe.
As conservative states moved to restrict clinic abortions post-Roe, medication abortions increased significantly. Data from the Guttmacher Institute indicates that medication abortions accounted for over 60% of all abortions in the US in 2023.
Evidence points to mifepristone being overwhelmingly safe, with fewer reported side effects than Viagra or penicillin, according to a CNN analysis.
In 2024, Louisiana filed a suit claiming that the Biden-era regulation conflicted with its abortion ban. A federal district court declined in April to restrict access to the drug while the Food and Drug Administration completes its safety review.
The Supreme Court previously considered this issue in 2024, unanimously rejecting a lawsuit against the FDA’s regulation. However, that ruling concluded on standing rather than direct access, suggesting that more challenges will likely reach the justices.
For now, the legal landscape surrounding mifepristone remains in flux, highlighting the continuing debate over abortion access across the United States.
